UK markets open in 2 hours 37 minutes

Akebia Therapeutics, Inc. (AKBA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.1500+0.0100 (+0.88%)
At close: 04:00PM EDT
1.1500 0.00 (0.00%)
After hours: 07:58PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 241.04M
Enterprise value 241.93M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.18
Price/book (mrq)N/A
Enterprise value/revenue 1.29
Enterprise value/EBITDA 158.33

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-18.44%
S&P500 52-week change 326.49%
52-week high 32.4800
52-week low 30.7800
50-day moving average 31.5058
200-day moving average 31.3157

Share statistics

Avg vol (3-month) 35.2M
Avg vol (10-day) 33.39M
Shares outstanding 5209.6M
Implied shares outstanding 6209.6M
Float 8190.4M
% held by insiders 11.91%
% held by institutions 127.30%
Shares short (30 Apr 2024) 411.86M
Short ratio (30 Apr 2024) 42.76
Short % of float (30 Apr 2024) 45.72%
Short % of shares outstanding (30 Apr 2024) 45.66%
Shares short (prior month 28 Mar 2024) 413.4M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin -22.99%
Operating margin (ttm)-45.63%

Management effectiveness

Return on assets (ttm)-8.43%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)187.22M
Revenue per share (ttm)0.97
Quarterly revenue growth (yoy)-18.70%
Gross profit (ttm)N/A
Net income avi to common (ttm)-43.03M
Diluted EPS (ttm)-0.2200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)41.96M
Total cash per share (mrq)0.2
Total debt (mrq)91.28M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.70
Book value per share (mrq)-0.13

Cash flow statement

Operating cash flow (ttm)-25.28M
Levered free cash flow (ttm)31.08M